Thaller S R, Kim S, Tesluk H, Kawamoto H
Department of Surgery, University of California, Davis, School of Medicine, Sacramento.
Ann Plast Surg. 1990 Dec;25(6):435-9. doi: 10.1097/00000637-199012000-00002.
Surgicel, which is commonly used as a hemostatic agent in clinical practice, is basically composed of oxidized regenerated cellulose. Skoog followed by Thilander and Stenstrom are credited with initially describing the use of Surgicel as a subperiosteal implant that could stimulate new bone formation in the closure of secondary palatal fistulae. Encouraged by these previous studies, we decided to investigate the effect of Surgicel and a new implant material, hydroxyapatite impregnated with collagen, on the split calvarial bone graft donor site. To do this, we used adult New Zealand White rabbits as our experimental model. Our study demonstrated histological evidence of both an increased quantity and earlier bony reformation, eventually reconstituting the surgical defect in the split calvarial bone graft donor site treated with Surgicel. Additionally, we found that this alloplastic implant material has potential in the reconstruction of the donor defect in selected patients.
速即纱在临床实践中常用作止血剂，其主要成分是氧化再生纤维素。斯科格之后，蒂兰德和斯滕斯特伦率先描述了将速即纱用作骨膜下植入物，可在闭合继发腭瘘时刺激新骨形成。受这些先前研究的鼓舞，我们决定研究速即纱和一种新的植入材料——胶原浸渍羟基磷灰石，对颅骨劈开植骨供区的影响。为此，我们以成年新西兰白兔作为实验模型。我们的研究显示了组织学证据，表明使用速即纱治疗的颅骨劈开植骨供区，骨量增加且骨重建更早，最终修复了手术缺损。此外，我们发现这种异体植入材料在特定患者的供区缺损重建中具有潜力。
